Met is the transmembrane tyrosine kinase cell surface receptor for hepatocyte growth factor (HGF) and is structurally related to the insulin receptor (INSR) tyrosine kinase. Here we report that the HGF-Met axis regulates metabolism by stimulating hepatic glucose uptake and suppressing hepatic glucose output. We show that Met is essential for an optimal hepatic insulin response by directly engaging INSR to form a Met-INSR hybrid complex, which culminates in a robust signal output. We also found that the HGF-Met system restores insulin responsiveness in a mouse model of insulin refractoriness. These results provide new insights into the molecular basis of hepatic insulin resistance and suggest that HGF may have therapeutic potential for type 2 diabetes in the clinical setting.
a r t i c l e s HGF was originally discovered because of its ability to stimulate primary cultures of hepatocytes to undergo DNA synthesis 1 and was subsequently identified as the ligand for Met (also known as the HGF receptor) [1] [2] [3] [4] [5] . In the liver, HGF is expressed and stored by specialized nonparenchymal cells known as the fat-storing stellate cells; HGF acts in a paracrine fashion on hepatocytes, which express Met but not HGF. As is true for INSR, Met is a heterodimer consisting of an α and a β subunit held together by disulfide bonds and is the most similar to INSR in terms of the overall structure of the receptor and the sequence of the kinase domain as compared to any other member of the receptor tyrosine kinase (RTK) subclass 6 . No substantial sequence homology exists between the extracellular domains of Met and INSR or their ligands, HGF and insulin, respectively. In the kinase domain, Met and INSR have a kinase regulatory loop that is composed of YDKEYY (which includes the specific tyrosines Tyr1230, Tyr1234 and Tyr1235) in Met and of YETDYY (which includes the specific tyrosines Tyr1146, Tyr1150 and Tyr1151) in INSR. Phosphorylation of the three tyrosine sites is essential for maximum upregulation of the catalytic activity of both Met and INSR 7 . Notably, neither Ron tyrosine kinase receptor, which is the closest relative of the Met receptor (based on its overall sequence and structural identity), nor any EGFR family members resemble INSR in having three tyrosine residues in their kinase regulatory loop ( Supplementary  Fig. 1 ). We therefore hypothesized that cellular signals emanating from the HGF-Met axis functionally overlap with those of the insulin-INSR system, including cues that control hepatic glucose metabolism, and that direct interactions between Met and INSR exists.
RESULTS

Met recruits and activates insulin receptor substrates
We first performed glucose uptake and glycogen synthesis assays using normal primary cultures of rodent and human hepatocytes as well as hepatocytic cell lines such as HepG2 and Hepa1-6. HGF significantly stimulated glucose uptake and glycogen synthesis to the same extent as insulin (Fig. 1a) . Insulin and HGF synergistically stimulated glucose uptake when a minimal dose of insulin was used (Fig. 1a) . Two particular insulin receptor substrate (IRS) proteins, IRS1 and IRS2 (refs. [8] [9] [10] [11] , are known to be recruited to INSR in response to insulin and to mediate glucose metabolism. HGF caused rapid recruitment of IRS1 and IRS2 to Met within 5 min of its administration (Fig. 1b) . Epidermal growth factor (EGF), a potent activator of hepatocyte proliferation, had no such effects (Fig. 1b) . Notably, insulin treatment resulted in association of the IRS proteins with Met (Fig. 1b) . Conversely, stimulation with HGF led to engagement of INSR with IRS2, as did stimulation with insulin (Fig. 1c) . Association of IRS proteins with Met was accompanied by robust tyrosine phosphorylation of both IRSs, which was pronounced by 5 min after HGF treatment ( Fig. 1d and Supplementary Fig. 2) .
In response to insulin, IRS1 or IRS2 can be phosphorylated on several tyrosine residues, including two conserved tyrosine residues (referred to as Tyr612 and Tyr895, where the position numbering corresponds to IRS1), and these two residues are known to engage phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) through p85 (also known as PIK3R or PI3K, regulatory subunit) and growth factor receptor-bound protein 2 (GRB2) or SHP2 (also known as PTPN11 or protein tyrosine phosphatase, non-receptor type 11), respectively 8 . Stimulation of hepatocytes with insulin or HGF induced tyrosine phosphorylation of both IRSs on these sites, as determined by immunoprecipitation for IRS and immunoblotting with antibodies to the specific phospho-sites (Fig. 1d) . HGF preferentially stimulated the Tyr895 site, whereas insulin efficiently stimulated Tyr612 (Fig. 1d) . a r t i c l e s 1 5 7 8 VOLUME 17 | NUMBER 12 | DECEMBER 2011 nature medicine Because Met, INSR and IRS associate with each other (see below), Met may interact with and activate IRS indirectly through INSR. To investigate this possibility, we performed kinase assays using a cell-free system that contained pure recombinant Met kinase, IRS1 and INSR kinase. Met by itself was capable of phosphorylating IRS1 at Tyr612 and Tyr895 (Fig. 1e) . Like INSR, Met harbors an IRS-binding motif (the QPEY motif in Met; Supplementary Fig. 1 ), as well as the YXXYY motif in the activation loop, which, when fully activated in INSR, is known to bind to IRS2 (ref. 8) . Together, these data indicate that Met is capable of directly interacting with and activating IRSs.
Downstream in the signaling pathway from INSR and IRSs is murine thymoma viral oncogene homolog 1 (Akt), which, upon activation, phosphorylates the transcription factors forkhead box O1 (FoxO1) and FoxO4, subsequently inhibiting their function by causing nuclear exclusion 12 . In time course studies, we discovered that HGF stimulation induced phosphorylation of FoxO1 and FoxO4 (Fig. 1f ) , which peaked at 30 min after stimulation and was sustained until the end point of the experiment (1 h) (data not shown).
Met and INSR form a molecular complex
To determine whether Met and INSR associate with each other, we performed coimmunoprecipitation studies using Hepa1-6 hepatocytic cells.
In the absence of HGF or insulin, cells did not have any detectable Met-INSR complexes. However, stimulation with HGF resulted in the formation of Met-INSR complexes (Fig. 2a) , and insulin treatment induced Met association with INSR, which coincided with INSR activation (at phospho-INSR Tyr1146; Fig. 2a) . HGF plus insulin also caused the formation of Met-INSR complexes, which occurred concomitantly with an enhancement of INSR activation (Fig. 2a) .
Given the above data, we aimed to determine whether Met directly transphosphorylates INSR. Therefore, we subjected purified recombinant human Met kinase (relative molecular weight (Mr) = 78 kDa) and INSR kinase (Mr = 70 kDa) containing only the cytoplasmic domains to kinase assays in the presence of 32 P-γATP (that is, hot kinase assays) to document de novo phosphorylation. Met or INSR incubated alone at low concentrations showed minimal kinase activity. However, the addition of Met to INSR resulted in robust tyrosine phosphorylation of INSR (Fig. 2b) . Immunoblotting confirmed the presence of both Met and INSR in the reaction and revealed that Met-induced INSR phosphorylation includes the phospho-Tyr1146 site (Fig. 2b) . We further established that Met tyrosine phosphorylates INSR using another type of recombinant INSR kinase that is polyhistidine (His) tagged, has an Mr of 37 kDa and is easily distinguished from recombinant Met kinase (which is glutathione S-transferase (GST) tagged and has an Mr of 78 kDa; Supplementary  Fig. 3a ). In similar experiments using recombinant EGFR kinase domain in hot kinase assays, we found that phosphorylation of INSR by Met is specific, as EGFR did not promote INSR phosphorylation ( Supplementary Fig. 3b ).
To investigate whether INSR activation by Met occurs in cells, we treated serum-deprived primary cultures of human hepatocytes with HGF, insulin or a combination of the two and assessed them for INSR activation. In the absence of their cognate ligands, Met and INSR showed minimal tyrosine phosphorylation in their activation loops. Insulin stimulated INSR, and HGF activated Met (Fig. 2c) . Notably, HGF also rapidly stimulated INSR in the kinase activation loop on Tyr1146 and Tyr1150 or Tyr1151 ( Fig. 2c and Supplementary Fig. 4) . Similar experiments using HepG2 cells showed that HGF also activated INSR on its C-terminal-tail Tyr1322 residue (Fig. 2d) . Tyr1322 is one of the multidocking sites in INSR that is responsible for engaging mediators such as PI3K. We then downregulated Met using an siRNA-mediated approach and noted a pronounced reduction in the amount of phospho-INSR (Fig. 2e) , suggesting that full INSR activation requires Met. We next used a tetracycline resistance protein (Tet)-regulated stable Hepa1-6 cell line that expresses a dominant-negative form of Met (DN-Met) 13 to determine whether tyrosine phosphorylation of INSR induced by Met depends on functional Met. DN-Met acts as a suppressor of Met tyrosine kinase, thus preventing Met activation induced by HGF (Fig. 3a) . HGF-induced phosphorylation of INSR and recruitment of INSR and IRSs to Met were dampened after induction of DN-Met ( Fig. 3b and Supplementary Fig. 5 ).
Met is involved in hepatic glucose homeostasis
To determine whether Met-INSR crosstalk functions in vivo, we first injected wild-type CD1 mice intraperitoneally (i.p.) with insulin (0.0002 U per g of body weight or 0.02 U per g of body weight, with two mice per dose) and assessed their liver extracts (as described above). The results indicated that INSR activation by insulin rapidly recruits Met to INSR and promotes Met interaction with IRS1, establishing that Met-INSR-IRS crosstalk is operational in hepatic tissue in vivo (Supplementary Fig. 6a) .
We then used a two-pronged approach to assess the importance of Met in glucose homeostasis in vivo. In the first part of our approach, we used loss-of-function models. We determined blood glucose concentrations in adult transgenic mice that express DN-Met under the transcriptional regulation of an albumin promoter enhancer (AlbDN-Met) 13 , thus limiting its expression to the liver. We found that these transgenic mice showed hyperglycemia under fasting conditions (the mean blood glucose for the AlbDN-Met transgenic mice was 145 mg dl −1 , compared to 87 mg dl −1 for nontransgenic littermate controls (P = 0.0062)) (Fig. 4a) . We next subjected the AlbDN-Met mice to a glucose tolerance test (GTT) and an insulin tolerance test (ITT). The mice showed a significantly reduced ability to dispose of glucose (Fig. 4b) and a significantly reduced response to insulin as compared to wild-type controls (Fig. 4c) . Further investigation showed that the formation of Met-INSR hybrid complexes was detectable in the nontransgenic mice but was diminished in the AlbDN-Met transgenic mice (Supplementary Fig. 6b ). 
a r t i c l e s
In a second loss-of-function approach we performed RNAimediated knockdown by delivering siRNA to the mouse liver 14, 15 to investigate the short-term effects of Met impairment on hepatic glucose homeostasis. We administered Met-specific siRNA (10 nmol in a single tail vein injection) to mice and then subjected them daily to GTT after overnight fasting. We performed daily GTT to ensure that we encompassed the nadir of the Met protein abundance. On day 1 after siRNA injection, we saw no difference in the rate of glucose clearance between the mice injected with Met-specific siRNA and the control mice (data not shown). However, on days 2 and 3 after siRNA injection, we detected a significant impairment of glucose clearance in the mice injected with Met-specific siRNA (Fig. 4d shows the data for day 3; the data from day 2 showed a similar pattern but are not shown here). Diminished glucose clearance occurred concomitantly with a significant reduction (an approximately 40% reduction; P = 0.0017) in Met protein abundance (Fig. 4d inset and  Supplementary Fig. 7 ). Met-specific siRNA had no effect on INSR expression or on hepatic histology (that is, we observed neither hepatic apoptosis nor necrosis) (data not shown).
HGF restores insulin responsiveness in diabetic mice
To further determine whether HGF regulates glucose homeostasis, we also performed gain-of-function studies. We chose ob/ob mice for these experiments because they are a well known model of insulin resistance and show dysregulated hepatic glucose output and fasting hyperglycemia. Notably, we found that systemic injection of recombinant HGF into fasting ob/ob mice suppressed the rise of endogenous blood glucose over the test period of 120 min as compared to saline-treated control mice (Fig. 5a) . Insulin administration (0.25 mU per g of body weight, which is a highly efficacious dose in wild-type lean mice) did not suppress the blood glucose spike in ob/ob mice (Fig. 5b) , but, when co-injected with HGF, the combination of the two profoundly blunted endogenous blood glucose elevation (Fig. 5c) . These data suggest that HGF and insulin act synergistically to normalize blood glucose. HGF, unlike insulin, did not induce overt hypoglycemia when administered to fasting normal lean mice (Fig. 5b) , suggesting that HGF has a tonic influence on maintaining blood glucose in a normal range.
We next subjected the ob/ob mice to GTT with or without insulin treatment. Again, insulin (0.25 mU per g of body weight) had no effect on regulating blood glucose concentrations in ob/ob mice. HGF had a modest but notable effect when administered alone (data not shown); however, co-treatment of insulin with HGF resulted in a much more pronounced improvement in regulating blood glucose (Fig. 5d) . In wild-type lean mice, insulin at the same dose (0.25 mU per g of body weight) markedly lowered blood glucose when animals were subjected to GTT, whereas HGF by itself showed a modest but significant effect (Fig. 5e) , suggesting that HGF can promote glucose disposal.
The elevation in the concentration of endogenous blood glucose that we observed in ob/ob mice after injection with saline or insulin (Fig. 5a,b) peaked at approximately 400 mg dl −1 , which is equivalent to the blood glucose concentration obtained when ob/ob or wild-type mice are injected with the 2 mg per g of body weight of exogenous glucose typically administered during a GTT. It is known that ob/ob mice, but not wild-type mice, have dysregulated hepatic glucose output and respond to stress (for example, blood sampling) by releasing an abnormally large amount of glucose into the blood, a response that mimics the effects of glucagon 16, 17 .
To test whether HGF suppresses glucagon-induced glucose output, we subjected ob/ob mice (after overnight fasting) to glucagon challenge (0.1 µg per g of body weight) with or without HGF. HGF suppressed glucagon-induced blood glucose elevation in ob/ob mice (similar to the results shown in Fig. 5a,b and data not shown). We then challenged the wild-type lean counterparts of the ob/ob mice (also in a fasting state) with glucagon to induce hepatic glucose production and found that treatment with HGF together with glucagon effectively dampened blood glucose elevation (Fig. 5f) . It is notable that glucagon only affects the liver because the glucagon receptor is expressed only on hepatocytes. In these studies, we found that HGF does not prevent the process of glycogenolysis per se (as determined by periodic acid-Schiff staining and liver glycogen content assays; data not shown), but it may affect other components of hepatic glucose production such as gluconeogenesis and glucose release.
To further explore the mechanism underlying HGF-induced suppression of blood glucose elevation, we assessed Met activation and signaling after systemic HGF injection in liver, adipose and skeletal muscle tissues. HGF administration activated Met in the liver within 15 min of injection but did not stimulate Met in adipose or skeletal muscle (Fig. 6a) . This is perhaps because injected HGF cannot reach these latter tissues because the liver picks up over 95% of systemically injected HGF and the kidney absorbs the remainder 18, 19 , as both the liver and kidney are Met enriched (Supplementary Fig. 8 ).
HGF caused phosphorylation of hepatic Akt (Ser473) (Fig. 6b and Supplementary Fig. 9 ) and FoxO1 (Thr24) within 15 min of treatment. As mentioned above, phosphorylation of FoxO1 promotes its exclusion from the nucleus. This causes its disengagement from target promoters and, as a result, repression of gene transcription. Of note, we found that FoxO1 was hypophosphorylated in ob/ob mice under fed conditions, suggesting that transcription of gluconeogenic target genes, . P values were determined by two-way ANOVA. ***P = 0.0001 between the groups, P < 0.0001 within a group (that is, at each time point), and P = 0.0002 for interaction between the two groups. (b) Blood glucose concentrations in fasted male ob/ob and lean mice (n = 5 per group) after injection of insulin (0.25 mU per g of body weight in saline) and/or HGF (as described above). The P values for ob/ob mice were determined by two-way ANOVA. ***P = 0.005 between the groups, P < 0.0001 within each time point, and P < 0.0001 for interaction between the two groups. (c) A compilation of the data from a and b showing the synergistic effects of HGF and insulin on blood glucose concentrations. (d,e) GTT in fasting ob/ob mice (n = 10 total) (d) or lean mice controls (n = 15 total) (e) injected systemically with glucose (1.5 mg per g of body weight) containing insulin (0.25 mU per g of body weight) or glucose containing insulin plus HGF. **P = 0.004 for ob/ob mice in d and for lean mice in e, *P = 0.018 for HGF compared to control, and **P = 0.001 for insulin compared to control determined by two-way ANOVA. (f) Glucagon challenge in fasted lean mice (0.5 µg per g of body weight by tail vein injection) with or without HGF. **P = 0.0023 between the groups, P < 0.0001 within each group (each time point), and P = 0.046 for the group interactions determined by two-way ANOVA. Error bars, mean ± s.e.m.
a r t i c l e s such as those encoding phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), is ongoing in these mice. In contrast to ob/ob mice, wild-type lean mice showed hyperphosphorylated FoxO1 in their livers (Fig. 6b) , confirming that the expression of gluconeogenic target genes is normally downregulated. PEPCK and G6Pase are the key rate-limiting enzymes in gluconeogenesis and glucose output, and the genes encoding them are transcriptionally driven by FoxO1. Analysis by western blot of hepatic tissues from lean mice treated with or without HGF showed a significant reduction in the amount of G6Pase protein by HGF (P = 0.013) and insulin (P = 0.002) (Fig. 6c) . In ob/ob mice that underwent glucagon challenge with or without HGF, HGF also significantly (P = 0.03) reduced hepatic PEPCK protein (Fig. 6d) and G6Pase protein abundance (data not shown). Additionally, we found that treatment of ob/ob mice with HGF caused a marked reduction in the amount of hepatic solute carrier family 2, member 2 (GLUT2) protein, as assessed by western immunoblot (Fig. 6e) and by immunohistochemistry (Fig. 6f ) . That HGF regulates GLUT2 is a new finding, as this transporter protein (also known as facilitated glucose transporter-2 or SLC2A2) has a crucial part in controlling the movement of glucose between the liver and blood in a bidirectional manner (that is, into and out of hepatocytes during the fed and fasted states, respectively).
The downregulation of PEPCK, G6Pase and GLUT2 proteins by HGF confirmed our gene array data, which showed that HGF injected into wild-type mice suppresses PEPCK, G6Pase and GLUT2 mRNA in the liver (Supplementary Table 1) . HGF injections also substantially modulated the mRNA abundances of pyruvate kinase, pyruvate carboxylase, lipase, fatty acid synthase, long-chain fatty acyl-CoA synthetase and glyceraldehyde-3-phosphate dehydrogenase (Supplementary Table 1 ).
DISCUSSION
Our studies describe a previously unidentified function for Met tyrosine kinase in governing hepatic glucose metabolism by directly interacting with and regulating the insulin receptor. These findings expand the existing knowledge base regarding the molecular action of insulin-INSR in glucose metabolism and hepatic insulin resistance. Mechanistic and biochemical studies showed that interaction of Met with INSR leads to activation of INSR by Met through formation of a Met-INSR hybrid that subsequently recruits and activates IRS1 and, to a greater extent, IRS2 in response to HGF or insulin. Notably, hepatic IRS2 is thought to be the major regulator of blood glucose 15 . Met stimulation seems to result in preferential phosphorylation of Tyr895 (compared to Tyr612) on IRS1 and IRS2 compared to insulin, which led to a more robust activation of Tyr612, indicating complementary mechanisms of action between the two growth factor-growth receptor pairs. The Tyr895 and Tyr612 sites of the IRSs engage the PI3K and MAPK pathways through p85, GRB2 and SHP2, respectively 8 , to promote cell growth and cell survival in addition to controlling metabolism. Based on our data, we propose that, in the liver (that is, in hepatocytes), Met cooperates with INSR, which leads to robust signaling by the Met-INSR complex to regulate glucose metabolism. Thus, signal intensity by INSR alone in the absence of Met is relatively limited (Fig. 6g) . We propose that the role of Met in glucose metabolism in the liver is to promote hepatic glucose uptake and suppress glucose production and output from hepatocytes into the blood.
As mentioned above, injected HGF only activated Met in the liver (and, to a much lower degree, in the kidney) but not in adipose tissue or skeletal muscle. Liver and kidney are epithelial tissues and, as such, highly express Met, whereas adipose and skeletal muscle are mesenchymal tissues and express relatively lower concentrations of Met. Indeed, Met and INSR are expressed at similar concentrations in the liver, but INSR is more abundant in adipose tissue and skeletal muscle as compared to Met. It is likely that, in vivo, HGF produced locally in the microenvironment of adipose and muscle tissues can reach adipocytes and myocytes (in a paracrine or autocrine manner) to activate Met and regulate glucose metabolism. Other researchers have reported that the 3T3-L1 adipocyte cell line and L6 myotube cells, a muscle-derived cell line, respond to exogenous HGF in vitro and show enhanced glucose uptake through the Gab-1-PI3K-GLUT-4 pathway without engaging IRS1 (refs. 20,21) . We also found that HGF is a potent activator of Gab1 and Akt in hepatocytes. A recent study focusing on the role of Met in promoting cell motility reported that IRS1, but not IRS2, is recruited to Met after stimulation with IGF1 in cultures of mouse embryonic fibroblasts (which express very low amounts of Met). This interaction required the tyrosines in IRS1 to be phosphorylated; however, IGF1 receptor (IGF1R) was seemingly not associated with Met 22 . These data suggest that the Met-INSR-IRS crosstalk we describe here may be specific to hepatocytes, which express high amounts of Met, INSR, IRS1 and IRS2.
Previous studies have reported a role for HGF-Met in hepatic lipid metabolism. Administration of the antidiabetic agent pioglitazone (a ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ)) induced Met expression, which, the authors postulated, may subsequently attenuate steatosis 23 . We previously reported that PPAR-γ binds to the HGF gene-proximal promoter and activates its expression 24 . Others have reported that HGF can ameliorate fatty liver induced by a high-fat diet 25 .
Our in vivo results suggest that HGF is a potent suppressor of hepatic glucose production and output in a setting of insulin resistance and that it can potentially restore insulin responsiveness. This notion is further substantiated by findings from our gene array studies, in which we found that administration of HGF to mice modulated hepatic mRNA expression of enzymes involved in glucose and lipid metabolism in a similar manner as insulin. It is notable that the pronounced effects of HGF on dampening stress-induced hyperglycemia could be caused, at least in part, by HGF influencing glucose uptake and/or release in non-hepatic tissues such as kidney (which, as mentioned above, is rich in Met). The kidney is well known for its ability to regulate blood glucose homeostasis through gluconeogenesis and glucose output as well as renal glucose reabsorption. The latter process involves transporter proteins such as GLUT2 and solute carrier family 5, member 2 (SGLT2) (also known as the sodium/glucose cotransporter SLC5A2) 26 . Thus, the kidney contributes to hyperglycemia in the diabetic setting 26 . It is conceivable then that HGF may have a therapeutic role in treating hyperglycemia in type 2 diabetes by its ability to directly influencing glucose metabolism in multiple organs such as liver (this study) and kidney and indirectly by promoting pancreatic beta cell growth and survival 27 . Therefore, further studies are warranted to investigate the efficacy and feasibility of HGF in the clinical management of diabetes.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. a r t i c l e s
